Skip to content

Replimune Group REPL Current ratio

Current ratio at other companies

Amgen logo
AmgenAMGN
1.3×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.5×+1.3×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
CG Oncology logo
CG OncologyCGON
31.3×+0.3×
Erasca, Inc. logo
Erasca, Inc.ERAS
9.5×-2.8×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on the most recent quarter.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's current ratio?
Replimune Group (REPL) reported current ratio of 5.6× in Q4 2025.
How has Replimune Group's current ratio changed year-over-year?
Replimune Group's current ratio decreased by 51.0% year-over-year, from 11.4× to 5.6×.
What is the long-term trend for Replimune Group's current ratio?
Over 4 years (2021 to 2025), Replimune Group's current ratio has grown at a -30.1% compound annual growth rate (CAGR), from 33.3× to 8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.